| Ident. | Authors (with country if any) | Title |
|---|
| 001519 (2009) |
Carolyn Saylor [États-Unis] ; Ekaterina Dadachova [États-Unis] ; Arturo Casadevall [États-Unis] | Monoclonal antibody-based therapies for microbial diseases |
| 001565 (2009) |
W. Huisman [Pays-Bas] ; B. E. E. Martina [Pays-Bas] ; G. F. Rimmelzwaan [Pays-Bas] ; R. A. Gruters [Pays-Bas] ; A. D. M. E. Osterhaus [Pays-Bas] | Vaccine-induced enhancement of viral infections |
| 001687 (2007) |
Masaji Okada [Japon] ; Yoshinobu Okuno [Japon] ; Satomi Hashimoto [Japon] ; Yoko Kita [Japon] ; Noriko Kanamaru [Japon] ; Yasuko Nishida [Japon] ; Yoshie Tsunai [Japon] ; Ruriko Inoue [Japon] ; Hitoshi Nakatani [Japon] ; Reiko Fukamizu [Japon] ; Yumi Namie [Japon] ; Junko Yamada [Japon] ; Kyoko Takao [Japon] ; Ritsuko Asai [Japon] ; Ryoko Asaki [Japon] ; Tetsuo Kase [Japon] ; Yuji Takemoto [Japon] ; Shigeto Yoshida [Japon] ; J. S. M. Peiris [Hong Kong] ; Pei-Jer Chen [Taïwan] ; Naoki Yamamoto [Japon] ; Tatsuji Nomura [Japon] ; Isao Ishida [Japon] ; Shigeru Morikawa [Japon] ; Masato Tashiro [Japon] ; Mitsunori Sakatani [Japon] | Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models |
| 001764 (2005) |
Dinesh S. Bangari ; Suresh K. Mittal | Development of nonhuman adenoviruses as vaccine vectors |
| 001786 (2005) |
Masaji Okada [Japon] ; Yuji Takemoto [Japon] ; Yoshinobu Okuno [Japon] ; Satomi Hashimoto [Japon] ; Shigeto Yoshida [Japon] ; Yukari Fukunaga [Japon] ; Takao Tanaka [Japon] ; Yoko Kita [Japon] ; Sachiko Kuwayama [Japon] ; Yumiko Muraki [Japon] ; Noriko Kanamaru [Japon] ; Hiroko Takai [Japon] ; Chika Okada [Japon] ; Yayoi Sakaguchi [Japon] ; Izumi Furukawa [Japon] ; Kyoko Yamada [Japon] ; Makoto Matsumoto [Japon] ; Tetsuo Kase [Japon] ; Daphne E. Demello [États-Unis] ; J. S. M. Peiris [Hong Kong] ; Pei-Jer Chen [Taïwan] ; Naoki Yamamoto [Japon] ; Yoshiyuki Yoshinaka [Japon] ; Tatsuji Nomura [Japon] ; Isao Ishida [Japon] ; Shigeru Morikawa [Japon] ; Masato Tashiro [Japon] ; Mitsunori Sakatani [Japon] | The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice |
| 001937 (1999) |
Douglas S. Zatechka Jr. [États-Unis] ; Nagendra R. Hegde [États-Unis] ; Kandasamy Hariharan [États-Unis] ; S. Srikumaran [États-Unis] | Identification of murine cytotoxic T-lymphocyte epitopes of bovine herpesvirus 1 |
| 001960 (1998) |
F. M. Fernandez [États-Unis, Argentine] ; M. E. Conner [États-Unis] ; D. C. Hodgins [États-Unis] ; A. V. Parwani [États-Unis] ; P. R. Nielsen [États-Unis] ; S. E. Crawford [Argentine] ; M. K. Estes [Argentine] ; L. J. Saif [États-Unis] | Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines |
| 001983 (1997) |
Terecita D. Yule [États-Unis] ; Mark B. Roth [États-Unis] ; Kimberly Dreier [États-Unis] ; Anthony F. Johnson [États-Unis] ; Melissa Palmer-Densmore [États-Unis] ; Kris Simmons [États-Unis] ; Robert Fanton [États-Unis] | Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease |
| 001A27 (1995) |
| Preparation of a helicase region coded by hepatitis C virus; hepatitis C virus recombinant helicase production via gene cloning and expression in Spodoptera frugiperda insect cell culture using baculovirus vector |
| 001A28 (1995) |
| Pathogen strain Borrelia burgdorferi ZS7 (DSM 5527); for the production of passive antibodies for the treatment of Lyme disease |
| 001A29 (1995) |
| New epitope-bearing portions of Entamoeba histolytica ; recombinant non-glycosylated epitope production and expression in prokaryote host cell, for application in a recombinant vaccine |
| 001A31 (1995) |
| Mengo virus as a vector for expression of foreign polypeptides; hepatitis A virus, HIV virus, rabies virus, foot-and-mouth-disease virus, coronat virus, Rous sarcoma virus, herpes virus, etc., live attenuated recombinant vaccine |
| 001A83 (1993) |
| Vaccine containing cattle papilloma virus-2 and/or cattle papilloma virus-4 L2 protein; for use as recombinant vaccine or in tumour therapy |
| 001A87 (1993) |
| Retrovirus-mediated recombinant fusion protein preparation; vector with Rous-sarcoma virus gag gene myristylation site for recombinant vaccine production in CV-1, COS-1, NIH3T3 or turkey embryo fibroblast cell culture as membranous particle |
| 001A89 (1993) |
| Peptides corresponding to regions of HPV-16 E1 and E2 proteins: human recombinant papilloma virus-16 E1 and E2 protein sero-reactive region and monoclonal antibody useful in cervix carcinoma vaccine, diagnosis |
| 001A92 (1993) |
| New nucleic acid encoding E2 protein of canine corona virus; dog corona virus recombinant E2 protein production; may be used in recombinant vaccine production |
| 001A93 (1993) |
| Induction of immunological response to mammal pathogen; rabies virus, cattle leukaemia virus, cat leukaemia virus or herpes simplex virus antigen gene cloning in an avipox virus vector for use as a recombinant vaccine |
| 001B31 (1992) |
| Vaccine comprising live attenuated or inactivated rotavirus strains; HRV 89-12C2, HRV 408, HRV 248 HRV 456 and/or CJN, for immunization against rotavirus illnesses |
| 001B32 (1992) |
| Vaccine comprising anti-idiotype antibody conjugate; induces production of neutralizing antibody (human monoclonal antibody, chimeric antibody or FAb, F(Ab′) 2 or Fv fragment) against HIV virus-1 |
| 001B37 (1992) |
| Recombinant pox virus containing Morbilli virus DNA; expression of e.g. measles virus haemagglutinin glycoprotein in host for construction of a potential recombinant vaccine against dog distemper virus |
| 001B38 (1992) |
| Recombinant feline corona virus-S protein; expressed as galactokinase fusion protein and useful as reconbinant vaccine, therapeutic and diagnostic agents for feline-infectious-peritonitis virus |
| 001B41 (1992) |
| Nucleic acid constructs, malaria polypeptides and vaccines; recombinant malaria serine-repeat antigen production in yeast for the construction of a recombinant vaccine |
| 001B42 (1992) |
| New gene fragment encoding rabies virus glycoprotein; DNA sequence expression in eukaryote cell culture and application to recombinant vaccine construction |
| 001B45 (1992) |
| Hepatitis C virus asialoglycoprotein-E1 and -E2; useful as vaccine or for diagnosis of non-A non-B hepatitis virus infection, or for concentrating or reducing HCV proteins in biological samples, and obtained by gene expression in yeast |
| 001B53 (1992) |
| Antigen composition comprising PEB1 and/or PEB3 antigen from Campylobacter jejuni ; useful as vaccine and for diagnosis of C. jejuni and Campylobacter coli infections |
| 001C34 (1989) |
| Synthetic peptide antigen corresponding to the major sites of T-lymphocyte recognition within the HIV virus envelope protein: recombinant vaccine production |
| 001C35 (1989) |
| Peptide capable of binding rubella immunoglobulin useful for rubella diagnosis and vaccine production; expression in Escherichia coli |
| 001C36 (1989) |
| Parasitic nematode vaccine for human and animal protection fusion protein expression |
| 001C37 (1989) |
| New human recombinant cytomegalo virus containing foreign gene: DNA sequence encoding HIV virus antisense mRNA or malarial surface antigen |
| 001C38 (1989) |
| Malaria vaccine peptide Plasmodium falciparum circumsporozoite protein gene cloning in vaccinia virus |
| 001C39 (1989) |
| Heterologous virus peptide immunogen production: recombinant vaccine production in L-cell, Chinese hamster ovary, C127 cell culture |
| 001C43 (1989) |
| Canine corona virus vaccine production by infected cell culture; effective against dog corona virus and dog parvo virus infection |
| 001C58 (1988) |
| Vaccine for swine trichinosis comprising inert newborn Trichinella spiralis newborn larvae emulsified with an adjuvant |
| 001C59 (1988) |
| Vaccine for immunizing cattle against lungworm comprising live immunogenic attenuated Dictyocaulus viviparus third stage larvae |
| 001C60 (1988) |
| Vaccine against varicella-zoster virus (causative agent of chicken pox) using a DNA segment encoding the protective immunogenic gB glycoproteins |
| 001C61 (1988) |
| Vaccine against transmissible-gastroenteritis virus of pigs; antigen from non-pathogenic pig respiratory-corona virus |
| 001C62 (1988) |
| Vaccine against feline infectious peritonitis virus is prepared from virus FIPV 79-1146 serially passaged in non-oncogenic cell until nonvirulent |
| 001C63 (1988) |
| Suppression of nonsense codon or frameshift mutation especially useful in vaccine production |
| 001C64 (1988) |
| Recombinant pox virus expressing pseudorabies virus antigens used as live vaccines, for producing subunit vaccine and for diagnosis |
| 001C65 (1988) |
| Recombinant Pseudomonas exotoxin produced by cloning of Pseudomonas aeruginosa DNA in Escherichia coli having low toxicity to human or mice cells but retaining enzymatic activity giving cell-specific immunotoxin; vaccine application |
| 001C66 (1988) |
| Peptide fragments immunoreactive with HTLV-III virus (HIV virus) antibody obtained by expressing cloned fragmented HTLV-II provirus nucleotide sequences; vaccine production etc. |
| 001C67 (1988) |
| Nucleic acid encoding a T4 glycoprotein used for treatment of AIDS and producing antibodies for use as a vaccine for immunization against AIDS |
| 001C68 (1988) |
| New avirulent Salmonella-Escherichia coli hybrid strains useful in live oral vaccine against enteric diseases including cholera |
| 001C70 (1988) |
| Multivalent pneumococcal vaccine and its preparation from polysaccharide purified from Pneumococcus |
| 001C75 (1988) |
| Genetically engineered vaccines for mycobacterial antigens comprising recombinant poxvirus, e.g. vaccinia virus, capable of expressing Mycobacterium leprae, Mycobacterium tuberculosis or Mycobacterium bovis antigens |
| 001C77 (1988) |
| Eimeria acervulina antigen isolation and use as a vaccine against fowl coccidiosis (US Equivalent) |
| 001C78 (1988) |
| Deactivated triple vaccine for abortus fever, Ibaraki disease and Akabane disease produced by incubation of the viruses in cell culture |
| 001C79 (1988) |
| Canine parvovirus vaccine preparation by growth of CPV-HP stem on dog tumour fibroblasts or renal cells |
| 001C80 (1988) |
| Candida guilliermondii immunobiological composition production by aerobic cultivation of the organism and extraction, used for diagnosis prophylaxis and treatment of infections, and as vaccine |
| 001D03 (1987) |
| adr-type hepatitis B virus surface antigen for vaccine production obtained by culture of human hepatoma cell strain huGK-14 |
| 001D04 (1987) |
| Vaccine for use in cases of sheep foot-rot comprising at least one protease of Bacteroides nodosus |
